

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **COMPLETION OF DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY**

Reference is made to the announcement of Viva Biotech Holdings (the “**Company**”) dated December 15, 2023 in relation to the disposal of 2.33% equity interest in VIVA Shanghai (the “**Announcement**”). Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the conditions precedent of the Equity Transfer have been fulfilled and Completion took place on December 27, 2023. Upon Completion, Raed Capital Holdings 2 Ltd is interested in approximately 2.33% of the registered capital of VIVA Shanghai, and the Group’s interest in VIVA Shanghai reduced from approximately 75.79% to 73.46%, and VIVA Shanghai remains a subsidiary of the Company whose financial results will continue to be consolidated in the financial statements of the Group.

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, December 27, 2023

*As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*